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SUMMARY 21 
The quality of clinical research in surgery has long attracted come under sustained criticism over the 22 
last 20 years. HHigh quality randomised trials have provedare more difficult to conduct in surgery 23 
than for drug treatments, and .  Mmany surgical treatments have therefore been adopted without 24 
adequate supporting evidence of efficacy and safety.  This evidence deficit can adversely affect 25 
research funding and re-imbursement decisions, slowing adoption of innovations, and can also 26 
permit widespread adoption of procedures which offer no benefit or cause harm turn out to be 27 
harmful or of no benefit.  Improvement in the quality of surgical evidence would therefore be very 28 
valuable. TClinical research has become more sophisticated in recent years, and the IDEAL 29 
Framework and Recommendations, launched in 2009, have addressed some of the methodological 30 
problems in surgical research specify desirable qualities for surgical studies,.  and outline an 31 
integrated evaluation pathway for surgery and similar complex interventions.  We used the IDEAL 32 
Recommendations to assess methodological progress in surgical research over time, assessed We 33 
therefore reviewed methodological progress in surgery, and the uptake and influence of IDEAL and 34 
identified the challenges to further methodological progress. . 35 
We used a small sampling study, using compliance with IDEAL Recommendations to compare quality 36 
in surgical research Comparing studies from the periods 2000 - 2004 and 2010-2014in two epochs 37 
ten years apart, to focus a review of progress, and looked for evidence about the adoption and 38 
impact of IDEAL, .  Wwe noted apparent improvement in some areas, including the use of standard 39 
outcome measures, adoption of CONSORT standards,  and evaluation of the quality of surgery and of 40 
learning curves, but no progress in  others, such as the use of qualitative research or transparent 41 
reporting of modificationschanges in procedures during early procedure development.  Better 42 
education about research, integration of evaluation work into routine practice and training, 43 
regulation and linkage of evaluation work to assessment and awards systems could foster further 44 
improvements in surgical evidence. IDEAL has probably contributed only slightly to the 45 
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improvements described to date, but its uptake is accelerating rapidly. , and tThe need for the 46 
integrated evaluation templatepathway it offers for surgery and other complex treatments is 47 
becoming more widely accepted.   48 
 49 
INTRODUCTION  50 
Just over 20 years ago, the Lancet published one of its most provocative Editorials since the era of 51 
Thomas Wakley.  Entitled “Surgical research or comic opera”, it lampooned clinical research in 52 
surgery, contrasting current practice with the principles of the  Evidence-Based Medicine 53 
movement(1).  Surgeons reacted with anger, claiming that they faced special problems which 54 
frequently invalidated an approach based solely on randomised controlled trials(2, 3).  Their protests 55 
were not widely accepted, but the controversy ignited eventually proved constructive.  Enquiry 56 
began into why randomised controlled trials (RCTs) seemed to be so difficult to conduct in surgery, 57 
and from these studies a picture emerged which partly justified the surgeons’ original objections(4, 58 
5). Expert consensus conferences involving surgeons, EBM experts and others developed a credible 59 
description of the process of evolution of innovative treatments, in surgery and other disciplines 60 
where complex skilled procedures require adaptation to each individual patient.  This construct was 61 
termed the IDEAL Framework, referencing the terms used for the sequential stages in the 62 
evolutionary process (Idea, Development, Exploration, Assessment and Long-term study)(6-8).  The 63 
Framework provided a theoretical basis for arguments against randomisation from the first patient 64 
in these complex interventions.  Each stage in the IDEAL Framework frames specific questions to be 65 
addressed, and: this led logically  to the development of the IDEAL Recommendations, a set of 66 
guidelines for study design and reporting aimed at answering these questions for each stage (See 67 
Table 1 for a recently updated version of both Framework and Recommendations)(8, 9). 68 
The IDEAL Recommendations have been widely recognised as a rational approach to developing an 69 
integrated evaluation pathway for surgery and other complex interventions.  Since they describe  70 
desirable properties for clinical studies of surgery, they have obvious potential as a yardstick for 71 
judging the methodological progress of surgical research.  In this article we look first at how surgical 72 
research has developed in the last 20 years, using adherence to the  IDEAL Recommendations as a 73 
measure of progress, .  We then consider what impact IDEAL has had to date, how surgical research 74 
could be further improved, and what role IDEAL could play in that process in the future.  and second 75 
at the development of IDEAL itself, assessing its evolution and its progress in terms of acceptance 76 
and adoption in the surgical community internationally.  77 
WHAT IS SURGICAL RESEARCH? 78 
Defining surgical research is challenging, and different definitions may be useful depending on the 79 
reasons for needing one. During the last 60 years we have seen the development of cardiac and 80 
vascular surgery, organ transplantation, joint replacement, minimally invasive surgery and most 81 
recently robotic surgery, advances of unquestionable importance to patients which have been based 82 
on surgical research.    However many leading university departments of surgery emphasise research 83 
on topics such as the molecular genetics of diseases treated by surgery, the immunology of organ 84 
transplantation and rejection, or stem cell treatments.  Perhaps because of this, the direct study of 85 
outcomes from technical innovation such as minimally invasive and robotic surgery and new 86 
surgically implanted devices has been taken forward just as much by “non-academic” surgeons as by 87 
professional researchers.   88 
In this article we have considered only studies of the outcomes of surgical techniques, i.e. papers in 89 
which the question addressed is around the effects of an operation, , either simply reporting the 90 
outcomes or comparing them to other treatment optionss.  ince tThe focus of methodological 91 
criticism of surgical research has always been on this evaluation of surgical efficacy and 92 
effectiveness, and comparisons of different time periods are clearly simpler if the types of study 93 
compared are restricted. 94 
HOW HAS IT CHANGED?  95 
Published surgical research has been steadily increasing in volume year on year.  Using search terms 96 
based on the above narrow definition of surgical research (see Appendix 1) we identified 41 surgical 97 
RCTs in PubMed for the year 2000, and 246 for 2014. During the same time, the number of RCTs 98 
recorded yearly on PubMed as a whole increased from 11,515 in 2000 to 27,426. Non-randomised 99 
surgical outcome studies also showed a several-fold increase during this time.  Randomised trials 100 
may be increasing somewhat as a proportion of surgical outcomes studies, but this trend is not yet 101 
so clear that we can be sure.  In 2000, RCTs represented 30%  (41 of 138) of all outcome studies 102 
identified by our search criteria, and this rose to just under 50% (208 of 422) by 2011, but the figures 103 
of  48% (218 of 458) in 2012 and 38% (217 of 564) in 2014 did not support the impression of a rising 104 
trend  (Figure 1).  105 
 METHODOLOGICAL TRENDS IN QUALITY: AN IDEAL ANALYSIS  106 
An analysis of surgical research based solely on the proportion of studies which are RCTs gives an 107 
inadequate view of the changes in surgical research over time, specifically because it does not 108 
acknowledge the importance of pre-RCT studies of innovations still undergoing modification. The 109 
IDEAL Recommendations specify a number of uncontroversial desirable features for clinical studies 110 
of surgical interventions, especially for these earlier stages of surgical research. Examining whether 111 
these specific features have become more prevalent in published work over the years allows us to 112 
look at the progress of surgical research methodology in greater depth and detail. The IDEAL 113 
Framework provides clear justification for the fact that It remains true that only a minority of 114 
published surgical research is made up of RCTs. , and indeed the IDEAL Framework provides clear 115 
justification for this.  However, in order for surgical research to make progress the validity and 116 
accuracy of the studies during the earlier stages of the evolution of new techniques prior to an RCT 117 
needs to improve in quality, as well as the RCTs themselves.  The 1990s critiques of the surgical 118 
literature were based largely on analysis of contemporary studies of techniques in these earlier 119 
stages IDEAL stages 2a and 2b, for which the retrospective case series was, at that time, the 120 
standard (and grossly inadequate) format for publication.  The IDEAL Recommendations specify 121 
desirable characteristics for early stage studies which the case series plainly lacked.  We were 122 
interested in whether compliance with specific IDEAL Recommendations had improved since the 123 
first IDEAL publication, suggesting progress in the direction IDEAL recommended.  We therefore 124 
conducted a sampling exercise looking at studies sampled studies from 2000-2004 and from 2010-125 
2014, the latter being the first full 5 year period after the publication of the original IDEAL articles 126 
(See Appendices 1 and 2 for details). This sampling exercise was not powered to demonstrate 127 
statistical significance, so our comments on the trends we found are necessarily tentative.   128 
SAMPLING SURVEY 129 
This article is principally intended as discussion and debate, and this sampling study of the changes 130 
in surgical research over time supports this by providing some objective evidence on trends: its’ 131 
methodology does not however allow us to draw firm quantitative conclusions from it.  We 132 
conducted a literature search designed to identify clinical studies of the outcomes of surgical 133 
techniques (for details of our search strategy see Appendix 1).  We then took random samples of 25 134 
papers from each of the two five-year subpopulations (200-2004 and 2010-2014), and compared 135 
them for the presence or absence of desirable characteristics specified by the IDEAL 136 
Recommendations (See Table 1). Several different random samples were taken to allow us to study 137 
different IDEAL Recommendations in the appropriate subgroup of studies, since some 138 
Recommendations apply only to specific stages in the IDEAL Framework.  Further details of our 139 
methods and reasoning can be found in Appendix 2.  Additional details and a list of the papers 140 
reviewed are available from the corresponding author. 141 
 Description of iterative changes in the procedure would be expected only in IDEAL 2a 142 
Development studies, and for this Recommendation we therefore sampled only from amongst 143 
papers which appeared to describe innovations at this stage, using the rules of thumb described by 144 
Pennell et al(9) to identify these.  145 
 IDEAL recommends that operator learning curves are evaluated before embarking on RCTs; 146 
we therefore searched only amongst reports of RCTs for evidence that learning curves were 147 
considered whilst deciding which centres should  enter patients. 148 
 IDEAL recommends the use of pilot and feasibility studies and qualitative studies to inform 149 
protocol development during the planning of RCTs, and we therefore selected only from amongst 150 
RCTs when analysing compliance with these recommendations. The Recommendations we studied 151 
and the classes of study from which the samples were selected are shown in Table 2. 152 
 153 
IDEAL RECOMMENDATIONS APPLICABLE TO ALL OUTCOMES STUDIES 154 
The proportion of papers reporting prospective (as opposed to retrospective) studies remained 155 
about the same over the decade between the two eras; it was 60% (15/25) in 2000-2004 and 64% 156 
(16/25) in 2010-14.  The procedure was reasonably well described in nearly all cases in both cohorts. 157 
By contrast information about the quality of surgery was rarely provided, although with some 158 
apparent improvement over time. In the later sample there was some attempt to evaluation of the 159 
quality of surgery in 5 papers (20%), but there was none (0%) in any of the papers from 2000-2004.  160 
The use of well-recognised standardised measures for outcomes, patient characteristics and other 161 
important data showed an apparent modest increase from 11/25 (44%) of 2000-2004 papers to 162 
15/25 (60%) of papers from 2010-2014.   163 
IDEAL RECOMMENDATIONS FOR  PRE-RCT STUDIES – STAGES 2A AND 2B 164 
The IDEAL recommendations for early development studies in Stage 2a stress the need for an 165 
account of changes to the procedure or indications during the development process. This remains 166 
relatively rare (16% (4/25) in both eras). Results at this stage should be presented sequentially so 167 
that trends and their associations with changes made may be more evident.  Only four papers (16%) 168 
followed these recommendations during the series in the 2000-2004 cohort, and the same 169 
proportion did so in 2010-2014, demonstrating  no trend over time.  170 
IDEAL RECOMMENDATIONS APPLICABLE PREPARATORY STUDIES FOR RCTS (STAGE 2B) AND RCTs 171 
(STAGE 3). 172 
The IDEAL Recommendations suggest prospective collaborative collection of non-randomised data 173 
as a preparatory step towards multicentre RCTs.  We found that the proportion of randomised trials 174 
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which referred to such data collection nearly doubled in the later sample (9/25 or 36%) compared to 175 
the earlier one (5/25 papers,  20%).  Although none of the sampled papers referenced the IDEAL 176 
Recommendations, it appears that stepwise progression from collaborating on prospective data 177 
collection to doing a trial together is becoming more common.  Prospective collaborative cohort 178 
studies increased considerably as a proportion of all non-RCTs between the eras sampled, whereas 179 
small case series with less than 50 patients have declined. Changes in both medicine and IT which 180 
have made collaborative data collection exercises less costly and inconvenient during the period 181 
under study, may have contributed to the change.  182 
Blinding or masking of outcome assessors in RCTs was reported in 6/25 (24%) of trials in the earlier 183 
period and in 10/25 (40%) in 2010-14.  There were no examples of the use of preparatory qualitative 184 
studies in any of the RCTs sampled in either epoch. The proportion of studies in which action was 185 
taken to address the issue of bias introduced by operator learning curves increased from 5 (20%) in 186 
the earlier epoch to 11 (44%) in 2010-2014. 187 
 Only two (8%) of the randomised trials sampled between 2000 and 2004 explicitly mentioned the 188 
use of pilot/feasibility work prior to the RCT, although 16 studies made reference to previous related 189 
work by one or more of the co-authors. None made reference to the CONSORT guidelines. Sample 190 
sizes ranged from 20 to 1289, with the largest studies testing ‘equivalence’. All studies carried out 191 
hypothesis testing but only 7 studies carried out a sample size calculation and were adequately 192 
powered for such testing. By 2010-2014 reference to previous pilot work had not increased (one 193 
study), but although again 16 studies referenced previous related work. However five studies (20%) 194 
made reference to the CONSORT guidelines, and 12 included a study flowchart. Sample sizes ranged 195 
from 11 to 597, with the largest study once again being an equivalence trial, and 12 studies reported 196 
the sample size calculation.  In both epochs absence of evidence of difference (p>0.05) in 197 
underpowered studies was routinely but incorrectly taken to be evidence of no difference between 198 
techniques.  The proportion of studies in which action was taken to address the issue of bias 199 
introduced by operator learning curves increased from 5 (20%) in the earlier epoch to 11 (44%) in 200 
2010-2014. 201 
ANALYSIS AND FORWARD VIEW 202 
Surgical research seems to be changing for the better, although not as fast as we might wish.  Over 203 
ten years there have been clear improvements in the proportion of studies using CONSORT and 204 
using standardised terminology to report key data items, and an increase in the percentage of 205 
surgical RCTs that have been developed from prior prospective collaborative data collection efforts 206 
(as recommended by IDEAL for Stage 2b).  The quality of surgical RCTs themselves appears to have 207 
improved in some respects too, as indicated by the A higher proportion of surgical RCTs trials now 208 
describeing blinding of outcome assessors, and there is better evaluation of the quality with which 209 
surgery iwas delivered (including evaluation of learning curves).  SIt is clear that surgeons are 210 
beginning to appreciate that properly designed preliminary studies are usually necessary before a 211 
successful surgical RCT if it is going to succeed, but the IDEAL proposition of an integrated evaluation 212 
pathway with identifiable stages building towards an RCT has not yet become widely accepted and 213 
understood.  Evidence of the distance still untravelled includes the persistently high  proportion of 214 
retrospective case series in the literature and the rarity of with which qualitative research has been 215 
used to inform the development of RCTs.  Another indicator of the persistent weaknesses of surgical 216 
evaluation is the list of surgical procedures introduced during the periods under study whose 217 
widespread adoption without an adequate research base has harmed patients or driven up costs – 218 
including robotic prostatectomy(10) and the metal-on-metal hip resurfacing techniques(11).  An 219 
IDEAL-type evaluation pathway would probably have mitigated these adverse outcomes and given 220 
us much clearer evidence on risks, benefits and costs. 221 
We know little about what  influences methodological  decision-making amongst surgical 222 
researchers, but some factors appear fairly obvious..  There are still strong career incentives for 223 
publishing poor research in surgery, particularly retrospective case series, and it is easy to find 224 
clinical journals that will accept them uncritically.  They are generally exempt from many of the 225 
regulatory hurdles which challenge prospective research and therefore represent a cheap, rapid 226 
route to publication.  As long as this form of research retains its value for career advancement it is 227 
unlikely to disappear.  On the other hand, the very difficulties which stimulated the development of 228 
IDEAL still make surgical trials difficult to organise, and there is no correlate for the abundant 229 
commercial funding available for pharma trials.  The weakness of basic training in the principles of 230 
clinical research for surgeons is a third important obstacle to progress.  The issues addressed by 231 
IDEAL are very familiar to surgeons, but most are unaware of previous work on the potential 232 
solutions.   233 
 What impact has IDEAL had since its inception in 2009?  It is difficult to evaluate the rate of diffusion 234 
of understanding of IDEAL through the surgical community.  Citation growth suggests an accelerating 235 
upward trajectory (BMC surgery, MS under review) but just as occurred with the EBM movement at 236 
its inception, understanding lags behind familiarity, and practical use is still further behind.  237 
UPractical uptake and use in the Health Technology Assessment community has however, made a 238 
strong start, with programmes in Canada(12) and the Netherlands(13) that use IDEAL to guide 239 
evaluation of medical technologies and devices.  A recently launched enterprise to offer device 240 
manufacturers a comprehensive evaluation service for innovative new products, EXCITE 241 
International(14), has embraced IDEAL as a central part of its methodology. ical strategy.  NIHR has 242 
specified IDEAL 2b-type studies in several recent calls, and dDiscussions about practical use of IDEAL 243 
in the NHS Commissioning through Evaluation project have also been held with NHS England and 244 
with NICE.   245 
WLooking more widely than the adoption of IDEAL, what changes could encouragespeed the 246 
development of high quality research in surgery?  T  As we noted in 2009, those who can influence 247 
the research environment are those responsible for educating and training surgeons and those who 248 
decide which research gets funding and publication(8).  The adoption of higher standards by surgical 249 
journals (especially surgical journals)  would be a major step forwards. , and some, such as the 250 
International Journal of Surgery, have begun to specify that IDEAL format studies are welcome(15).  251 
Journal editors could, relatively easily, challenge the publication of traditional case series and 252 
request IDEAL Development or Exploration studies instead, except in very  the rare situations where 253 
a case series is the only reasonable study design.  This   Adoption of these formats, and the 254 
integrated pathway they belong to, could help to reduce research waste by lowering the prevalence 255 
of small ad-hoc mini RCTs or single arm studies trying out a new technique with no future 256 
implementation pathway or plan.: this would be an important contribution to reducing research 257 
waste.  Clear support messages from research funders for that they will support composite 258 
proposals incorporating IDEAL-type pre-RCT pilot/feasibility studies to prepare the ground for a trial 259 
would quickly ill be important inmodify transforming the behaviour of the clinical research 260 
community.  It is encouraging that bodies such as the UK’s NIHR are beginning to experiment with 261 
IDEAL 2b-like studies, but they have as yet made no clear policy statement..  Whilst IDEAL has 262 
received virtually no direct opposition, there is a tangible reluctance amongst some funders to 263 
extend it a welcome.  This appears to be based on the (incorrect) perception that it challenges the 264 
principles of conventional medical research methodology, because of its championing of 265 
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uncontrolled study designs for some questions where no comparison between treatments is 266 
involved.  Presenting a case for IDEAL which reconciles true believers and sceptics on the role of 267 
RCTs in medical research is an impossible task, but open debate needs to be encouraged.  Silent 268 
passive resistance which evades discussion is unscientific and can only retard the search for a better 269 
framework for evaluating surgery and other complex interventions. 270 
If our aim is to continually enhance surgical research quality, the historical origins of modern science 271 
can point us to what catalyses a spirit of systematic enquiry within communities.  There is an 272 
excellent case that the Enlightenment, which ushered in the scientific revolution, was bought about 273 
by the rejection of dogma and the enhancement of basic educational attainment (16).  The 274 
complaint, voiced 20 years ago, that surgeons (and doctors in general) were surprisingly ill-educated 275 
about the principles of scientific methodology for investigating medical treatments is equally valid 276 
today, even in the countries where EBM has flourished.  Medical schools and postgraduate surgical 277 
training programmes are still failing to produce graduates who understand the methodological basis 278 
of clinical research and are able to apply this knowledge.  Correcting this will require more than just 279 
courses of study, since this type of complex applied knowledge can only be thoroughly incorporated 280 
through experiential learning.  Current surgical training in most countries separates academic and 281 
clinical work in an artificial and unhelpful way, with segments for dedicated “research time” and 282 
separate career tracks for academic and non-academic surgeons.  As we saw with the minimally 283 
invasive and robotic revolutions, this risks creating a situation where the drive to innovate and the 284 
ability to evaluate are separated, to the detriment of evidence-based progress.  Having a clinical 285 
workforce who are not afraid to set up simple early-stage data collection efforts which will yield 286 
valid and useful results would be a major contribution to improving both quality and quantity in 287 
surgical research.  One very welcome recent development has been the successful movement to 288 
establish surgical trainee research collaborative movements in the UK*.  These groups give trainees 289 
practical participative experience of research, and have demonstrated their ability to recruit patients 290 
at impressive rates and minimal cost.  Their ability to develop RCTs on important questions is limited 291 
by the short tenure and lack of political power of their memberships’ situation, but they have 292 
enormous potential to conduct IDEAL 2b studies rapidly and effectively, and to use these to drive the 293 
funding and development of a subsequent RCT.   294 
As well as opportunities to do clinical research as an integral part of training, achieving true 295 
integration of research and practice will require appropriate incentives for both trainees and 296 
established surgeons in “non-academic” posts.  The distinctions we currently make between 297 
research, audit and quality improvement are often unhelpful to this integration, and it may be more 298 
useful to talk of involvement in scientific evaluation.  Linking involvement in high-quality evaluation 299 
to appraisal, tenure and rewards structures may be helpful, but so may public recognition, and 300 
opportunities to develop other initiatives.  Making institutional approval for the development of 301 
innovative practice conditional on agreement to collect and submit appropriate data and submit it to 302 
the host institution, or for publication, would be a powerful way of enhancing evidence 303 
accumulation. Regulation may also help.  The current pharmaceutical industry evaluation paradigm, 304 
which has hugely improved the evaluation of new drugs, can be largely attributed to regulatory 305 
action in the wake of the Thalidomide disaster(17).  The regulatory framework  can influence the 306 
success and integration into clinical practice of Registries, as the success of Sweden in this area 307 
shows(158).  However regulation is usually most effective where popular opinion has already been 308 
won round to the ideas behind it, as the examples of restrictions on drink driving and smoking in 309 
public places illustrate.  Regulation may also fail to predict future research trends and developments.   310 
VISION FOR THE FUTURE 311 
SAs this review has shown, surgical research is getting better, although it still has a long way to go.  It 312 
was unfairly maligned in the first place, as understanding of the real problems it faced was under-313 
developed 20 years ago.  The IDEAL Framework and Recommendations have probably contributed 314 
only in a minor way to the improvements seen so far, but their influence is growing, they are very 315 
useful as a yardstick to measure progress, and they represent a serious attempt to create a new 316 
paradigm for surgical research methodology in the future.  The idea of a logical series of study 317 
questions and types based on the realities of how surgical operations evolve is clearly of value, and 318 
where IDEAL proves imperfect it is likely to be either modified or replaced by a better version, rather 319 
than by a return to methodological anarchy.  Because complex interventions typically require a 320 
period of iterative improvement before reaching a stable form, they cannot be subjected to 321 
immediate valid comparisons with alternatives until this phase is over. The variety of influences on 322 
outcome which can be generated by subject heterogeneity and by variations in the quality of 323 
intervention delivery, especially whilst operators are learning, is practically infinite.  Defining a 324 
subject group and a version of the intervention for a trial will therefore require a both a basis for 325 
decision making and considerable negotiation. Substantial prospective empirical data clearly 326 
represent a more reliable basis than theory combined with small datasets full of contextual biases.  327 
Hence collaborative collection of non-randomised data to assist with decision making its justified 328 
wherever complexity impedes definition of the study population or the intervention. 329 
These principles  vision of “no innovation without evaluation” applyies beyond the confines of 330 
surgerysurgery and quasi-surgical treatments, and beyond conventional academic research. The 331 
concept principle of integrated stepwise evaluation, beginning with a study of development of the 332 
innovation and proceeding through more comprehensive evaluation of its properties and uses 333 
before comparing it with alternatives, seems applicable to complex interventions in many fields, 334 
both in healthcare and other domains. A version of IDEAL for evaluating therapeutic devices was 335 
published last year(169), and plans for using IDEAL in radiotherapy(1720), physiotherapy(18)[Paez A 336 
et al, Physical Therapy, accepted, in press], and acupuncture[Prof REF Xin Sun, personal 337 
communication] are being implemented.  Psychological therapies and complex social or quality 338 
improvement interventions are other areas where it may prove useful. 339 
The current version of the IDEAL Framework and Recommendations is clearly not the last word on 340 
the subject, but a work in progress.  How it may need to be modified depends to a large extent on 341 
how clinical research methodology itself evolves.  For example, IDEAL’s current form is predicated on 342 
the assumption that RCTs will remain the “gold standard” methodology for comparing treatments.  343 
This seems likely, given their obvious structural superiority, but there is a danger that their 344 
increasing expense and regulatory complexity, combined with reluctance to participate amongst 345 
patients in cultures which value the individual’s right to choose as paramount, and competition from 346 
the application of sophisticated risk adjustment techniques to very large observational datasets may 347 
reduce their pre-eminence in the future.  However even a major change such as this would merely 348 
require the Framework to be adapted, rather than abolished: in other words, if IDEAL did not already 349 
exist, it would be necessary to invent it.   350 
Now that a viable alternative is beginning to emerge, the culture of surgical case series and other 351 
weak study designs should be consigned to history, and an integrated evaluation pathway for 352 
surgery using methodology appropriate to the task should be adopted. 353 
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Table 1. Summary of the IDEAL Framework and Recommendations 2017 
   IDEAL Framework 
(Description of stage of evolution of intervention) 
IDEAL Recommendations  
(For stage-specific study design and reporting) 
Stage 1 
Idea 
First in human  
Purpose: Proof of concept 
Number & Types of Patients: Single digit; highly 
selective. 
Number & Types of Surgeons: Very few; innovators@ 
Output: Description of intervention or procedure 
Status of Intervention: Evolving; at inception stage 
Reporting Methods: Structured case reports 
Outcomes Reported: Proof of concept; technical 
achievement; dramatic success; adverse events, 
surgeon views of the procedure  
 
Stage Endpoint: Once a decision is made to conduct a 
series of cases, i.e. to proceed to stage 2a. 
 Provide full details of patient selection, technique and 
outcomes and of patients not selected during the time frame, 
and why. 
 Use standard well-defined measures for reporting outcome 
and patient characteristics 
 Use a structured reporting system eg, SCARE checklist. 
 Make the above information available to peers regardless of 
whether outcome is favourable or not. 
 Informed consent should clearly explain status of procedure 
and impossibility of quantifying risks 
Stage 2a 
Development 
 
Iterative modification of the 
intervention until a stable version is 
achieved. 
Design: Single centre/single 
intervention; case series/prospective 
cohort 
Purpose: Development of procedure 
Number & Types of Patients: Few; Selected 
Number & Types of Surgeons: Few; innovators and 
some early adopters 
Output: Technical description of procedure and its 
development, with explanation of reasons for changes 
Intervention: Evolving; procedure development towards 
a stable optimised version. 
Methods: Prospective development studies (small 
prospective cohort studies) 
Outcomes: Mainly safety, technical and procedural 
success. 
 
Stage Endpoint: When the procedure is considered 
optimised, and stable enough to allow replication in 
Stage 2b. There should be no intent at this point to 
make further major modifications. 
 Make protocol for study available 
 Use standard well-defined measures for reporting 
outcome and patient characteristics 
 Report and explain all exclusions 
 Report all cases sequentially with annotation and 
explanation of changes to indication or procedure, and 
when and why they took place. 
 Display main outcomes graphically showing cases 
sequentially to illustrate the above. 
 Informed consent should explain current status of 
intervention and consequent uncertainties around risk** 
 
Stage 2b 
Exploration 
 
Collaborative prospective data collection 
and analysis aimed at achieving 
consensus on key issues, to determine if 
an RCT is feasible, and to define its 
design features.  Intended as a bridge 
from observational to comparative 
evaluation. 
 
Purpose: Achieving consensus between surgeons and 
centres on the parameters for an RCT (if possible) 
Number & Types of Patients: Many; broadening 
indication to include all potential beneficiaries 
Number & Types of Surgeons: Many; innovators, early 
adopters, early majority@ 
Outputs: Effect estimate for the intervention based on a 
large sample, allowing power calculations; Analysis of 
learning curves; estimate of influence of pre-specified 
technical variants and patient subgroups on outcome. 
Qualitative research to determine operator and patient 
values; Increased mutual confidence amongst 
operators. 
Intervention: The procedure is stable in individual 
hands but variation exists between operators; 
acceptable variants are subsequently defined by 
analysis of pooled results 
Method: Prospective multi-centre exploration cohort 
study or pilot/feasibility multicentre RCTs.  
Outcomes: Safety; clinical outcomes (specific/graded); 
short-term outcomes; patient centred/reported 
outcomes; feasibility outcomes 
 
Stage Endpoints: Demonstrate that technique can be 
more widely adopted; and, Demonstrate that 
progression to RCT is desirable and feasible 
 Make protocol for study available 
 Use standard well-defined measures for reporting outcome 
and patient characteristics 
 Participate in collaborative multi-centre co-operative data 
collection, incorporating feasibility issues such as:  
o estimating effect size,  
o defining intervention quality standards,  
o evaluating learning curves, 
o exploring subgroup differences,  
o eliciting key stakeholder values and preferences,  
o analysis of adverse events: 
 Hold a pre-planned consensus meeting prior to progressing 
to an RCT, to identify feasibility and ability to recruit, 
operator eligibility on basis of learning curve analysis, 
intervention and comparator definitions, appropriate patient 
selection criteria, primary endpoint. 
Stage 3 
Assessment 
Definitive comparative evaluation of 
main efficacy and safety aspects of new 
technique against current best 
treatment. 
Purpose: Comparative effectiveness testing 
Number & Types of Patients: Many; expanded 
indications (well-defined) 
Number & Types of Surgeons: Many; early majority@ 
Output: Comparison with current standard therapy  
Intervention: Stable, with acceptable variations clearly 
defined 
Method: RCT with or without additions/modifications; 
alternative designs (cluster, preference RCTs, stepped 
wedge, adaptive designs) 
Outcomes: Clinical outcomes (specific and graded); 
potentially  Patient Reported outcomes , Health 
 Register on an appropriate international register (e.g., 
clinicaltrials.gov) 
 Use standard well-defined measures for reporting outcome 
and patient characteristics 
 Incorporate information about patient and clinician values 
and preferences in design of consent information and 
procedures, and outcome measures.   
 Adhere to Reporting guidelines: 
CONSORT update of 2010 with extension for non-
pharmacological treatments  
COMET 
TIDieR 
Economic outcomes 
 
Stage Endpoints: Clear valid evidence on relative 
effectiveness of innovation; and, Identification of 
issues requiring long term monitoring. 
SPIRIT (for RCT protocol design) 
 
Stage 4 
Long term monitoring 
Purpose: Surveillance 
Number & Types of Patients: All eligible 
Number & Types of Surgeons: All eligible 
Output: Description; audit; recording of regional and 
local variations; quality assurance; risk adjustment; 
detection of indication creep 
Intervention: Stable 
Method: Registry; routine database; rare-case reports  
Outcomes: Rare events; long-term outcomes; quality 
assurance  
 
Stage Endpoints: dependent on lifecycle of 
device/procedure.  
Registries for devices – IDEAL-D 
Registries at earlier stages of IDEAL 
 Registries may begin from the earliest stages of human use 
 Registry datasets should be defined by the clinical community 
with patient input 
 Datasets should be simple, cheap and easy to collect 
 Curation of registries by clinical community is desirable 
 Funding of registries should be agreed between government 
and commercial interests but kept separate from curation 
 Patient Consent for use of registry data in research should be 
broad and where possible automatic 
 
 
@ Terms used under this heading refer to the classification of Everett Rogers (Diffusion of Innovations, 4th Ed, 1995) 
*Registries should be organised according to the IDEAL recommendations and should be available for enrolment at any Stage 
**Patient consent should always be informed by a summary of the outcomes from previous IDEAL Stages  
 
 
TABLE 2 
 
        2000-2004   2010-2014  Absolute difference (95% CI) 
IDEAL Recommendation – no./total no. (%)          percentage points 
Use of standardised terminolology    11/25 (44)   15/25 (60)  16 (-13.6 to 42.3) 
Definition and description of procedure   20/25 (80)   22/25 (88)  8 (-15.8 to 31.1) 
Prospective data collection     15/25 (60)   16/25 (64)  4 (-24.1 to 31.3) 
Explanation of modifications during early studies (2a)*  4/25 (16)   4/25 (16)  0 (-23.5 to 23.5) 
Prior analysis of learning curves in pre-RCT studies$  5/25 (20)   11/25 (44)  24 (-4.5 to 48.2) 
Use of quality control measures    0/25 (0)   5/25 (20)  20 (-1 to 41.3) 
Use of qualitative research to define RCT questions (3)$  0/25 (0)     0/25 (0)  0 (-16.6 to 16.6)   
Use of prior prospective cohort study to prepare for RCTs (3)$ 5/25 (20)   9/25 (36)  16 (-11.4 to 40.7) 
Mention of pilot or feasibility studies to prepare for RCT (3)$ 2/25 (8)   1/25 (4)  - 4 (-23.9 to 15.5) 
Blinding reported in RCTs (3)$     6/25 (24)   10/25 (40)  16 (-12.2 to 41.2) 
 
Proportions are reported for random samples of surgical outcome studies from the whole search population, except for: 
 * A random sample taken from the population of all cohort studies reporting < 50 cases over < 10 years in < 3 centres (A surrogate for Development stage 
studies) 
$ A random sample from the population of all RCTs 

